Uroporphyrinogen decarboxylase (URO-D) is a cytosolic heme-biosynthetic enzyme that converts uroporphyrinogen to coproporphyrinogen. Defects at the uroporphyrinogen decarboxylase locus cause the human genetic disease familial porphyria cutanea tarda. A splice site mutation has been found in a pedigree with familial porphyria cutanea tarda that causes exon 6 to be deleted from the mRNA. The intron/exon junctions on either side of exon 6 fall between codons, so the resulting protein is shorter than the normal protein, missing only the amino acids coded by exon 6. The shortened protein lacks catalytic activity, is rapidly degraded when exposed to human lymphocyte lysates, and is not detectable by Western blot analysis in lymphocyte lysates derived from affected individuals. The mutation was detected in five of 22 unrelated familial porphyria cutanea tarda pedigrees tested, so it appears to be common. This is the first splice site mutation to be found at the URO-D locus, and the first mutation that causes familial porphyria cutanea tarda to be found in more than one pedigree. (J.
Introduction
Uroporphyrinogen decarboxylase (URO-D)' is the fifth enzyme in the heme biosynthetic pathway and catalyzes the removal of four carboxyl groups from uroporphyrinogen to form coproporphyrinogen. The carboxyl groups are removed in a stepwise fashion from the acetate moiety of each of the pyrrole rings that make up the porphyrin macrocycle (1) . The mechanism and number of catalytic sites are unknown, but models have been proposed with from one to four active sites (2) (3) (4) . Unlike other decarboxylases, no cofactors are involved in catalysis (1) . The cDNA and gene for human URO-D have been isolated and sequenced (5, 6) . The human enzyme is a single polypeptide of 367 amino acids with a molecular weight of 40,831.
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1. Abbreviations used in this paper: EB, Epstein-Barr; f-PCT, familial porphyria cutanea tarda; HEP, hepatoerythropoeitic porphyria; PCR, polymerase chain reaction; URO-D, uroporphyrinogen decarboxylase.
Two human diseases, familial porphyria cutanea tarda (f-PCT) and hepatoerythpoeitic porphyria (HEP), are associated with inherited defects of URO-D (7, 8) . In f-PCT, the defect is inherited as an autosomal dominant trait and URO-D activity is usually half-normal in all tissues both by immunoreactive and catalytic assays. In HEP, URO-D activity is usually 5-10% normal and the disorder is due to the inheritance of mutant alleles from each parent (8). The dermal photosensitivity and uroporphyrinuria characteristic of both diseases are more pronounced in HEP than in f-PCT. A point mutation in the coding region ofthe URO-D gene has been identified in HEP (281 gly-*glu, reference 8), which produces a catalytically active but unstable protein. We previously described a point mutation in a family with f-PCT. The mutation resulted in a single amino acid change at position 281, but the substitution (281 gly-.val, reference 9) was different from the one described in HEP. This mutation also resulted in a catalytically active but unstable protein. The 281 gly-*val mutation could not be identified in other pedigrees with f-PCT suggesting that f-PCT, like HEP, is genetically polymorphic (9) .
Northern and Southern blotting experiments (10) have shown that there are no major deletions or rearrangements at the URO-D locus in families with f-PCT and that URO-D mRNA is present in normal amounts (11) . The URO-D gene is -3 kb in length and includes 1O exons (6) . We describe here the characterization of a point mutation that causes the deletion of exon 6 from URO-D mRNA derived from a previously described pedigree with f-PCT (pedigree A, reference 11). This point mutation was identified in five of 22 unrelated pedigrees with f-PCT.
Methods
cDNA synthesis, PCR amplification, cloning, and sequence analysis. Guanidine HCO was used to extract total RNA from Epstein-Barr (EB) virus transformed lymphocytes derived from the proband (1 1). 2 ,ug of total RNA were used as a template for single-stranded cDNA synthesis (12) , and 1/5 of the resulting cDNA was used as template for PCR amplification (13 Screening other individualsfor the mutation. Genomic DNA from three normal individuals, nine affected members from the same pedigree, and 21 unrelated affected individuals were PCR amplified as described above. The amplified products were slot-blotted to nitrocellulose filters and hybridized with a 32P-labeled oligonucleotide that contained the mutation (5'-GTGCCCAGCTGAGTCCT-3', the exon 6-intron 6 junction, see Results) as described previously (9) . The blots were stripped and rehybridized with a normal probe (5'-GTGCCC-AGGTGAGTCCT-3'). Hybridization and washing conditions were as previously described (9) .
In vitro degradation studies. RNA was made by transcribing cDNAs from pBluescript KS in vitro using T7 RNA polymerase after linearization of the plasmid with Eco RI (17) . "5S-Methionine-labeled URO-D was translated from RNA transcripts of cloned normal and mutant cDNA (9) Results URO-D cDNAs derived from an affected member of a f-PCT pedigree were polymerase chain reaction (PCR) amplified and revealed two sizes of URO-D cDNA upon agarose gel electrophoresis ( Fig. 1 A) . Northern analysis was carried out on total RNA from both normal and affected individuals and the results suggested that the size difference found in the PCRamplified cDNA was also present in the mRNA. The limited resolution of formaldehyde-agarose gels used for northern analysis, however, did not clearly separate the two URO-D mRNA species (Fig. 1 B) . The PCR amplified URO-D cDNA was then cloned into pBluescript, and plasmid DNA purified from individual clones used as template for sequencing. Sequence analysis of eight individual clones revealed that three clones contained a deletion of 162 bases from positions 491-655. This corresponded exactly to exon 6 of the URO-D gene (Fig. 2) . Several clones of each size were sequenced to determine if possible point mutations were due to PCR errors or were real mutations. No new point mutations were found in either allele, although several silent mutations and an A-)G change at position 325 (resulting in a ser-ugly substitution found in other normal URO-D cDNAs, reference 9) were noted in both alleles. PCR amplification was carried out using oligonucleotide primers specific for the URO-D gene from the middle of exon 5 to the middle of exon 7. The PCR products were cloned and sequence analysis of individual clones indicated that three of the clones were completely normal at their intron-exon junctions while five contained a G--C point mutation at the first position of the 5' end of intron 6 (Fig. 3 ).
-GGCATGGAGGTGACCATGGTACCTAGCAAAGGACCCAGCTTCCCAGAGCCATTAAGAGAA In vitro translation was carried on RNA transcribed from pBluescript containing either the normal or the mutant cDNA sequence. Electrophoresis of the labelled in vitro translation products on 10% polyacrylamide gels revealed that the deleted cDNA produced a shortened URO-D protein (Fig. 4 A) . The normal and deleted cDNAs were cloned into the bacterial expression vector pKK233-2. Western blot analysis of lysates from bacteria expressing the normal and deleted cDNAs were found to produce the normal and shortened URO-D protein (Fig. 4 B) . To determine ifthe shortened URO-D was stable in the cell, we carried out two experiments. In the first, Western blots were carried out on lysates from lymphoblasts derived from affected and unaffected members of the pedigree using a rabbit anti-URO-D antibody. These showed that URO-D protein in affected individuals is roughly half that in normal individuals and no band was visible that corresponded to the mutant protein (Fig. 4 C) . In the second experiment, in vitro translated 35S-labeled normal and mutant URO-D proteins were exposed to lymphocyte lysates, aliquots removed every 4 h for 16 h, and then subjected to electrophoresis on acrylamide SDS gels. The amount ofURO-D remaining at each timepoint was determined by densitometry of the autoradiograms (Fig.  5) . Linear regression analysis ofthe data indicated a half-life of 69 h for the normal protein and 19 h for the mutant protein.
Bacterially expressed normal and shortened URO-D proteins were assayed for URO-D catalytic activity using either uroporphyrinogen (octacarboxyl) or terial and human URO-D activity, so assays were also performed on bacterial lysates derived from cultures that did not have the expression vector. The normal length URO-D had significant levels of catalytic activity with both substrates, while the mutant URO-D protein had no activity with either substrate. The bacterial control also had no measurable activity (Fig. 6) .
Dot blots of PCR amplified DNA from nine affected and two normal individuals of the pedigree and from 21 unrelated individuals with familial PCT were hybridized with an oligonucleotide probe that corresponded to the mutant DNA sequence. Results (Fig. 7 A) indicated that all nine affected individuals from the pedigree had the same mutation. DNA from the two normal individuals did not hybridize to the mutant probe. DNA from affected members of four other unrelated PCT pedigrees hybridized to the mutant probe. The dot blots were stripped and rehybridized with a similar oligonucleotide probe that matched the normal sequence. This probe hybridized to all of the DNA samples (Fig. 7 B) , as expected in heterozygotes for a dominantly inherited trait. An internal control of cloned mutant genomic DNA was also dot blotted, and as expected, hybridized with the mutant probe but not the normal probe (Fig. 7) .
Discussion
This is the first splice site mutation to be found at the URO-D locus. Previously described mutations at the URO-D locus have been point mutations in coding regions causing instability ofthe mutant URO-D protein (8, 9 ). An interesting feature of this splice site mutation is that an exon is deleted during splicing. The intron-exon junctions on either side of the miss- (24) . Splice site sequence requirements have been studied extensively with in vivo and in vitro splicing systems (23, 25) . Site directed mutagenesis of conserved sequences at the 5' intron splice site skipping rarely occurs with in vivo systems but is common with in vitro splicing systems (25). Naturally occurring splice site mutations that lead to exon skipping have rarely been reported (26) . Mutations causing the skipping of exons 6 and 28 in the pro-a2(I) collagen chain mRNA have been reported (26, 27) . Each of these mutations caused an in-frame exon deletion which resulted in short, inactive proteins. Tromp and Prockop (26) suggested that the preferred splicing pathway for a gene determines if an exon will be skipped or an intron will be left in the aberrant mRNA. In the case of the URO-D mutant described here, the preferred pathway would be to remove intron 6 before intron 5. If intron 5 were normally removed first, then exon 6 would be retained and intron 6 would likely fail to splice and remain in the mutant mRNA. Our data are consistent with the hypothesis that splicing of one intron in a multi-intron gene is dependent on the splicing of at least some of the other introns.
Several other factors could be invoked to explain how exon 6 in the URO-D pre-mRNA is skipped. First, we assume that the cell will attempt to splice out intron 6 . The G-*~C mutation would prevent this if no cryptic splice sites were available so the next splice attempt would be intron 5. Why would the splicing of intron 5 include exon 6 and intron 6? In vitro splicing studies have shown that 5' intron mutations that lead to skipping of the previous exon cause a superlariat that includes the preceding intron and exon as well as the following intron (25). One possibility is that the lariat branch point sequence of the normally spliced intron 5 may be "out-competed" by the branch point sequence in intron 6. In the absence of the mutation, intron 6 would be spliced out first and the lariat branch site would be unavailable to compete during the splicing of intron 5. In the URO-D gene, there is no sequence in intron 5 that completely matches the consensus YNYURAY branch point sequence (28, 29) but several such sequences are present in intron 6 (Fig. 3) . Branch point sequences are usually 18-37 nucleotides upstream from the 3' splice site (28), but in some cases the branch point is much further away (30) . In either case, the polypyrimidine tract is usually adjacent (downstream) to the branchpoint sequence. Intron 6 does not contain a polypyrimidine tract adjacent to any of the putative branch point sequences. Therefore, it is problematic to assign branch point sequences in either intron 5 or 6 based on sequence alone. Branch point sequences are not well conserved in higher eukaryotes, and site-directed mutagenesis of branch points have shown that deviating from the consensus branch point sequences does not completely inhibit splicing (29, 31) . Some studies have shown that better consensus branch point sequences lead to more efficient splicing (29), which could explain our results.
The most important factor in determining the result of a 5' intron splice site mutation seems to be whether or not cryptic splice sites are present (23) . If none are available, the possible effects of the mutation would be to leave the intron in or to include the preceding intron and exon in the lariat to form a superlariat, thus skipping the exon (25, 26) . The next important factor may be the preferred splicing pathway (32) . The normal order ofsplicing would determine ifan exon were to be skipped. If the preceding intron were already removed, superlariat formation could not occur. If it had not yet been spliced then superlariat formation could occur possibly by branch point competition or some other mechanism (Fig. 8) The amount of URO-D protein measured by immunoelectrophoresis in affected members of the pedigree described here was half normal, as was URO-D catalytic activity (1 1). However, the amount of URO-D mRNA measured by densitometry of Northern blots (11) was normal in affected pedigree members, indicating that the mutation does not affect the stability of the mRNA. The shortened protein is less stable in vitro than the normal protein, but it may be difficult to compare protein half lives measured in vitro with in vivo measurements. We have previously noted that the in vitro measurement of a mutant URO-D protein indicated an 8-h half-life of URO-D, whereas in vivo measurements from pulse-chase experiments in cultured lymphocytes indicated a much shorter half-life, substantially less than 4 h (9). Western blot analysis of lymphocyte lysates derived from affected pedigree members revealed that steady-state amounts of URO-D protein are about half that of normal members and there was no band corresponding to the mutant protein, indicating that steadystate levels of the mutant protein in vivo is very low. On the basis of our Western blots, previous immunoelectrophoresis experiments (1 1), and our in vitro measurements we conclude that the shortened protein is rapidly degraded in the cells.
The half-normal amount of URO-D enzyme does not explain the accumulation and excretion of uroporphyrin as URO-D is not the rate-limiting step in heme biosynthesis (33) . Substrate accumulation is organ specific, occuring only in the liver, implying that URO-D does become rate limiting in hepatocytes of patients expressing the f-PCT clinical phenotype. The finding of half-normal activity of URO-D in liver biopsy specimens from patients with f-PCT may represent an artifact as the assay is carried out ex vivo with diluted liver homogenates. Under the assay conditions putative URO-D inhibitors (such as iron, porphyrins, or other compounds) would also be diluted. In patients clinically affected with f-PCT, one must assume that the product of the normal allele is inhibited by some unknown mechanism. This is illustrated by the observation that many carriers of defective URO-D alleles never develop clinical symptoms.
The active site of URO-D is unknown although experiments with sulfhiydryl-modifying agents indicate that cysteine residues may be involved (34) . Kinetic data of purified bovine, chicken, and human URO-D suggest that there may be more than one active site, one catalyzing the initial decarboxylation of uroporphyrinogen and the others decarboxylating intermediates leading to the final product, coproporphyrinogen (34) (35) (36) . We measured catalytic activity of the shortened URO-D with two different substrates to determine if the mutant protein could decarboxylate one substrate but not another. The results indicate that the shortened protein cannot decarboxylate uroporphyrinogen or pentacarboxyporphyrinogen. The deletion of 54 amino acids from URO-D could significantly alter the tertiary structure of the protein, so it is not surprising to find a total loss ofcatalytic activity. We can draw no conclusions about the number or position of the active site(s) from our results. This is the first mutation responsible for PCT to be found in more than one pedigree. It was found in five of 22 pedigrees tested. Most of these pedigrees were collected in a single geographic region of the United States. It is possible that at least some of the pedigrees are related, but no evidence of this was found in their family histories. Homozygous defects at the URO-D locus have been shown to cause HEP, a very rare (17 cases reported worldwide as of 1987, reference 37) disease. The mutation causing HEP that has been characterized to date produced unstable but active URO-D (8) so that some residual steady-state catalytic activity remained. The splice site mutation we have described would probably not be found in a homozygous state because the mutant gene product is totally inactive, and homozygosity would be lethal. If the majority of f-PCT cases are caused by splice-site mutations with a similar effect, then this would explain the rarity of reported HEP.
